Gain Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $7.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Gain Therapeutics’ promising developments in their Parkinson’s disease treatment. The company’s lead candidate, GT-02287, has shown positive initial results in a Phase 1b trial, demonstrating favorable safety and early efficacy signals in motor function, which were presented at a recent international congress. The anticipation of full 90-day data by the end of 2025 is a significant milestone, as it could further validate the therapeutic potential of GT-02287.
Additionally, GT-02287’s mechanism as an allosteric modulator aims to restore enzyme activity impaired by genetic mutations or aging, showing promise in preclinical models by reducing neuroinflammation and protecting neurons. The ongoing trial has been extended to allow dosing for up to 12 months, with exploratory endpoints including biomarker analyses and functional outcomes. This comprehensive approach and the potential for GT-02287 to be a disease-modifying treatment underpin McCarthy’s optimistic outlook and Buy rating for Gain Therapeutics.
In another report released today, Roth MKM also reiterated a Buy rating on the stock with a $6.00 price target.